Series A+ · BiotechVivacta Biotechnology: Series A+Develops in vivo CAR-T cell therapies for cancer and autoimmune diseasesPublished Oct 4, 2026By RoundOS Funding deskFunding historyApr 29, 2026Series A+ · This round$50MSourcesprnewswire.com↗
WyLWyL provides home nursing, personal care and medically supported housing in Japan.~¥1.5BUndisclosed · Nov 18, 2026
PulmoGatePulmoGate develops remote specialist review and medical AI tools for interstitial lung disease.~¥330MSeed · Nov 18, 2026
Isomorphic LabsBuilds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas$5BSeries C · Nov 17, 2026
NovAccelDevelops compact superconducting accelerators to produce medical radioisotopes.~¥290MPost-seed extension · Nov 17, 2026